![]() a vaccine).Īcuitas Therapeutics is a private biotechnology company located in Vancouver, British Columbia, Canada developing novel LNP carriers for mRNA and other nucleic acid therapeutics, including technology developed under limited license from Arbutus Biopharma Corporation. Such therapeutic proteins could replace a missing or defective protein, be an antibody to protect against infection, or provide a protective immune response (i.e. Synthetic mRNA can be introduced into a cell using Acuitas LNP carriers to direct the cell to produce a therapeutic protein. This information is transcribed into a message (mRNA), which then migrates out of the nucleus and is translated into the specific protein. Information that codes for a specific protein is contained on genes in the cell nucleus. Messenger RNA is a natural molecule that allows cells to produce proteins. In addition it exemplifies the concept of using the liver as a "protein factory" and the viability of repeat dosing" said Thomas Madden, Ph.D., President and Chief Executive Officer of Acuitas Therapeutics. Weissman and his colleagues illustrates the potential for mRNA-LNP therapeutics to provide passive immunotherapy against HIV-1 and potentially against other infectious diseases. ![]() Importantly a single injection of VRC01 mRNA-LNP protected humanized mice from an intravenous HIV-1 challenge in a dose-dependent manner. Further, weekly administrations of 1 mg/kg mRNA-LNP maintained trough antibody concentrations of ~40 µg/mL. In a paper published today in Nature Communications, Acuitas' scientists and academic researchers lead by Drew Weissman, MD, PhD, a professor of Infectious Diseases in the Perelman School of Medicine at the University of Pennsylvania showed that a single injection of mRNA-LNP encoding the anti-HIV-1 antibody VRC01 (1.4 mg/kg) resulted in plasma antibody concentrations of ~170 µg/mL at 24 hours. VANCOUVER, British Columbia, Ma/PRNewswire/ -Īcuitas Therapeutics Inc., a private biotechnology company developing state-of-the-art lipid nanoparticle (LNP) delivery technology for messenger RNA (mRNA), announced today publication of data demonstrating that mRNA encoding a broadly neutralizing antibody delivered in an Acuitas LNP carrier protects humanized mice from HIV-1 challenge.
0 Comments
Leave a Reply. |